NO20050569L - Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette - Google Patents

Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette

Info

Publication number
NO20050569L
NO20050569L NO20050569A NO20050569A NO20050569L NO 20050569 L NO20050569 L NO 20050569L NO 20050569 A NO20050569 A NO 20050569A NO 20050569 A NO20050569 A NO 20050569A NO 20050569 L NO20050569 L NO 20050569L
Authority
NO
Norway
Prior art keywords
treatment
heart failure
severe heart
drug
procedure
Prior art date
Application number
NO20050569A
Other languages
English (en)
Other versions
NO335369B1 (no
NO20050569D0 (no
Inventor
Atsushi Ozaki
Yosuke Maki
Osamu Sato
Yoshitaka Yamamura
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20050569(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NO20050569D0 publication Critical patent/NO20050569D0/no
Publication of NO20050569L publication Critical patent/NO20050569L/no
Publication of NO335369B1 publication Critical patent/NO335369B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sammendrag Fremgangsmåte for behandling av alvorlig hjertesvikt, som omfatter å administrere til en pasient en effektiv mengde av en benzazepinforbindelse (1): hvor R1 er H eller halogen, R2 er OH eller -NR5R6 (R5 og R6 er H eller lavere alkyl), R3 er H, halogen, lavere alkyl eller lavere alkoksy, R4 er halogen, lavere alkyl eller lavere alkoksy, eller et salt derav, og et farmasøytisk preparat som inneholder benzazepinforbindelsen (1) eller et salt derav, og anvendelse av forbindelsen (1) eller et salt derav til fremstilling av et medikament for behandling av alvorlig hjertesvikt.
NO20050569A 2003-02-24 2005-02-02 Anvendelse av en bestemt benzazepin-forbindelse eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament egnet for behandling av alvorlig hjertesvikt, og medikament derav NO335369B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44887803P 2003-02-24 2003-02-24
PCT/JP2004/002085 WO2004073716A1 (en) 2003-02-24 2004-02-23 Method for treating severe heart failure and medicament therefor

Publications (3)

Publication Number Publication Date
NO20050569D0 NO20050569D0 (no) 2005-02-02
NO20050569L true NO20050569L (no) 2005-11-22
NO335369B1 NO335369B1 (no) 2014-12-01

Family

ID=32908667

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050569A NO335369B1 (no) 2003-02-24 2005-02-02 Anvendelse av en bestemt benzazepin-forbindelse eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament egnet for behandling av alvorlig hjertesvikt, og medikament derav

Country Status (24)

Country Link
US (2) US7423032B2 (no)
EP (2) EP1596868B1 (no)
JP (2) JP4771937B2 (no)
KR (1) KR100706727B1 (no)
CN (1) CN100577171C (no)
AR (1) AR043259A1 (no)
AT (1) ATE411803T1 (no)
AU (2) AU2004212842B9 (no)
BR (1) BRPI0405657A (no)
CA (1) CA2493475A1 (no)
CY (1) CY1108583T1 (no)
DE (1) DE602004017283D1 (no)
DK (1) DK1596868T3 (no)
ES (1) ES2315640T3 (no)
HK (1) HK1084037A1 (no)
MX (1) MXPA05001623A (no)
MY (1) MY143740A (no)
NO (1) NO335369B1 (no)
PL (2) PL218069B1 (no)
PT (1) PT1596868E (no)
RU (2) RU2346689C2 (no)
SI (1) SI1596868T1 (no)
TW (1) TWI322689B (no)
WO (1) WO2004073716A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
PL1968990T3 (pl) 2005-12-27 2015-06-30 Otsuka Pharma Co Ltd Rozpuszczalny w wodzie związek benzoazepinowy i jego kompozycja farmaceutyczna
JP5076327B2 (ja) * 2006-02-01 2012-11-21 味の素株式会社 分岐鎖アミノ酸の心不全適応
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
NZ581126A (en) * 2007-05-15 2012-04-27 Otsuka Pharma Co Ltd Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
WO2011104269A1 (en) 2008-02-26 2011-09-01 Jenavalve Technology Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
WO2011147849A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
JP6563394B2 (ja) 2013-08-30 2019-08-21 イェーナヴァルヴ テクノロジー インコーポレイテッド 人工弁のための径方向に折り畳み自在のフレーム及び当該フレームを製造するための方法
WO2016177562A1 (en) 2015-05-01 2016-11-10 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
EP4183371A1 (en) 2016-05-13 2023-05-24 JenaValve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
WO2018138658A1 (en) 2017-01-27 2018-08-02 Jenavalve Technology, Inc. Heart valve mimicry
CN110174474B (zh) * 2019-05-24 2022-02-18 石家庄四药有限公司 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法
CN112121051B (zh) * 2020-09-30 2021-06-18 郑州大学 莫扎伐坦在制备抗消化道肿瘤药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753677A (en) * 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
DE69026708T2 (de) 1989-10-20 1997-04-03 Otsuka Pharma Co Ltd Benzoheterozyklische verbindungen
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
TW249201B (no) 1992-07-02 1995-06-11 Otsuka Pharma Co Ltd
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法
TW354762B (en) 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
JP2694319B2 (ja) 1993-12-24 1997-12-24 大塚製薬株式会社 抗潰瘍剤
JP3002766B2 (ja) * 1994-12-09 2000-01-24 大塚製薬株式会社 脳浮腫治療剤
JPH10120592A (ja) 1996-10-22 1998-05-12 Otsuka Pharmaceut Co Ltd メニエール病乃至メニエール症候群治療剤
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
ES2272341T3 (es) 2000-01-26 2007-05-01 Astellas Pharma Inc. Combinaciones de inhibidores de enzima y de antagonistas.
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
US20030008860A1 (en) * 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
ES2288899T3 (es) * 2000-10-04 2008-02-01 Astellas Pharma Inc. Uso de un antagonista de vasopresina tal como conivaptan en la fabricacion de un medicamento para el tratamiento de la hipertension pulmonar.
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
DE602004017283D1 (de) 2008-12-04
US20050187210A1 (en) 2005-08-25
HK1084037A1 (en) 2006-07-21
US7749993B2 (en) 2010-07-06
AU2004212842B2 (en) 2009-01-08
BRPI0405657A (pt) 2005-07-19
PL218069B1 (pl) 2014-10-31
CY1108583T1 (el) 2014-04-09
CN1700919A (zh) 2005-11-23
NO335369B1 (no) 2014-12-01
ES2315640T3 (es) 2009-04-01
AU2004212842B9 (en) 2009-03-05
RU2005102110A (ru) 2005-09-20
KR100706727B1 (ko) 2007-04-12
RU2008133654A (ru) 2010-02-20
TW200418489A (en) 2004-10-01
EP1596868B1 (en) 2008-10-22
US20080214523A1 (en) 2008-09-04
PL404315A1 (pl) 2013-08-05
TWI322689B (en) 2010-04-01
MY143740A (en) 2011-07-15
WO2004073716A1 (en) 2004-09-02
AU2004212842A1 (en) 2004-09-02
ATE411803T1 (de) 2008-11-15
NO20050569D0 (no) 2005-02-02
DK1596868T3 (da) 2008-12-08
CA2493475A1 (en) 2004-09-02
CN100577171C (zh) 2010-01-06
PL373432A1 (en) 2005-08-22
JP2011148806A (ja) 2011-08-04
JP2006518731A (ja) 2006-08-17
EP1596868A4 (en) 2006-03-29
PT1596868E (pt) 2009-01-14
MXPA05001623A (es) 2005-04-25
EP2000142A1 (en) 2008-12-10
RU2346689C2 (ru) 2009-02-20
SI1596868T1 (sl) 2008-12-31
KR20050105972A (ko) 2005-11-08
AU2009201109A1 (en) 2009-04-09
EP1596868A1 (en) 2005-11-23
AR043259A1 (es) 2005-07-20
JP4771937B2 (ja) 2011-09-14
US7423032B2 (en) 2008-09-09

Similar Documents

Publication Publication Date Title
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
IN2015DN01132A (no)
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
MY142551A (en) Substituted diaryl heterocycles, process for their preparation and their use as medicaments
EP1803721A4 (en) INNOVATIVE GLUCITOL DERIVATIVE, PRECURSOR OF THE MEDICINAL PRODUCT AND SALT THEREOF, AND A THERAPEUTIC AGENT FOR DIABETES CONTAINING THE SAME
NO20065904L (no) Terapeutiske forbindelser
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
SE9901573D0 (sv) New compounds
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
NO20064811L (no) 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase
RS20070077A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflamatory diseases
NO20045222L (no) Benzosyrederivater som modulatorer av PPAR alfa og gamma
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
RU2008126389A (ru) Производные 1,1- диоксотиоморфолинилиндолилметанона для применения в качестве модуляторов гистаминаз(н3)
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
SE9901572D0 (sv) New compounds